Literature DB >> 22897792

Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer.

Masaki Tomita1, Tetsuya Shimizu, Takanori Ayabe, Toshio Onitsuka.   

Abstract

AIMS: The relationship between the maximum standardized uptake values (SUVmax) on positron emission tomography (PET) and serum carcinoembryonic antigen (CEA) level in non-small cell lung cancer (NSCLC) patients was investigated.
METHODS: Consecutively, 197 surgically resected NSCLC patients with preoperative staging including serum CEA and PET were reviewed retrospectively.
RESULTS: When patients were subdivided into two groups based on the median value of the SUVmax (6.6), the 5-year survival of patients with a high SUVmax was 63.20%, which was significantly worse than patients with a low SUVmax (87.29%, P = 0.0004). The 5-year survival of patients with normal and high serum CEA level was 82.70 and 51.08%, respectively (P < 0.0001). Univariate and multivariate analyses indicated the independent prognostic impact of the SUVmax and serum CEA level. Patients with both low SUVmax and normal serum CEA level had favorable prognosis, whereas those with both high SUVmax and high serum CEA level had poor prognosis.
CONCLUSION: Preoperative SUVmax and serum CEA level are independent prognostic factors for survival in NSCLC. The combined use of preoperative SUVmax and serum CEA level might be a better prognostic indicator.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897792     DOI: 10.1111/j.1743-7563.2012.01549.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  9 in total

1.  Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma.

Authors:  Hui Yu; Xiuying Huang; Zhihua Zhu; Yi Hu; Wei Ou; Lanjun Zhang; Ningning Zhou
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

2.  Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Authors:  Kai-Hsiung Ko; Hsian-He Hsu; Tsai-Wang Huang; Hong-Wei Gao; Daniel H Y Shen; Wei-Chou Chang; Yi-Chih Hsu; Tsun-Hou Chang; Chi-Ming Chu; Ching-Liang Ho; Hung Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

3.  Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis.

Authors:  Xiao-Bin Wang; Jie Li; Yi Han
Journal:  Tumour Biol       Date:  2014-07-15

Review 4.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 5.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

6.  Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.

Authors:  Jian-Guo Zhao; Ya Hu; Quan Liao; Zhe-Yu Niu; Yu-Pei Zhao
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 7.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jing Liu; Min Dong; Xiaorong Sun; Wenwu Li; Ligang Xing; Jinming Yu
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

8.  Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.

Authors:  Jinghua Chen; Junxian Xia; Jiacheng Huang; Ruilian Xu
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

9.  Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients.

Authors:  Dangfan Yu; Kaiqi Du; Taifeng Liu; Guojun Chen
Journal:  Int J Mol Sci       Date:  2013-05-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.